675 results on '"Krempf, Michel"'
Search Results
152. Plasma lipidome characterization using UPLC-ESI-HRMS and ion mobility of hypertriglyceridemic patients on nicotinic acid
153. A relevant glucose-insulin dynamics model for type 1 diabetes
154. [Does a slight overweight increase life expectancy?]
155. A consensus statement on lipid management after acute coronary syndrome
156. Bioavailability of starch and postprandial changes in splanchnic glucose metabolism in pigs
157. Noninvasive tracing of human liver metabolism: comparison of phenylacetate and apoB-100 to sample glutamine
158. IRES-dependent translation of the long non coding RNA meloe in melanoma cells produces the most immunogenic MELOE antigens
159. Comparison of gas chromatography–mass spectrometry and gas chromatography–combustion–isotope ratio mass spectrometry analysis for in vivo estimates of metabolic fluxes
160. Multiplexed peptide analysis for kinetic measurements of major human apolipoproteins by LC/MS/MS
161. Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody
162. Carotid and femoral atherosclerotic plaques show different morphology.: Patterns of Peripheral Arterial Disease
163. Nicotinic Acid Accelerates HDL Cholesteryl Ester Turnover in Obese Insulin-Resistant Dogs
164. Effects of Extended-Release Nicotinic Acid on Apolipoprotein (a) Kinetics in Hypertriglyceridemic Patients
165. A Long-Term Model of the Glucose–Insulin Dynamics of Type 1 Diabetes
166. Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey
167. Liraglutide 3.0 mg Reduces Body Weight and Improves Cardiometabolic Risk Factors in Adults with Overweight/Obesity: The SCALE Obesity and Prediabetes Randomised Trial
168. Additional Analyses of the Weight-lowering Efficacy of Liraglutide 3.0 mg in Adults with Overweight and Obesity: The SCALE Obesity and Prediabetes Randomized Trial
169. Liraglutide 3.0 mg Reduces Body Weight and Improves Health-Related Quality of Life (HRQoL) in Overweight or Obese Adults without Diabetes: The SCALE Obesity and Prediabetes Randomized, Double-Blind, Placebo-Controlled, 56-Week Trial
170. Direct and maternal n-3 long-chain polyunsaturated fatty acid supplementation improved triglyceridemia and glycemia through the regulation of hepatic and muscle sphingolipid synthesis in offspring hamsters fed a high-fat diet
171. Abstract P214: Patient and Physician Factors Influence Decision-Making in Hypercholesterolemia
172. Use of advanced cluster analysis to characterize seafood consumption patterns and methylmercury exposures among pregnant women
173. PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia
174. Use of advanced cluster analysis to characterize seafood consumption patterns and methyle mercury exposures among pregnant women
175. The fenofibrate suppresses PCSK9 and eliminates its response to statins, via PPARalpha
176. CA-047 - Les patients et les soignants rêvent d’un parcours de soins optimisé ! Étude de faisabilité auprès de patients atteints de diabète de type 2 lors de l’initiation d’une insuline basale
177. Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) is repressed by the Peroxisome Proliferator Activated Receptor alpha (PPARa)-ligand fenofibric acid
178. Proprotein convertase subtilisin/kexin type 9 (PCSK9) expression is regulated by insulin, sterol regulator element binding protein 1C (SREBP 1c) and the peroxisome proliferator-activated receptor a (PPARa)
179. Fasting induces hyperlipidemia in mice overexpressing PCSK9
180. Proprotein Convertase Subtilisin/Kexin type 9 is repressed by PPARa and its overexpression during fasting results in massive hypertryglyceridemia
181. Proprotein convertase subtilisin/kexin type 9 (PCSK9) expression is regulated by insulin, an its overexpression during fasting results in hyperlipidaemia
182. Proprotein convertase subtilisin/kexin type 9 is regulated by insulin, SREBP-1C and pparalpha
183. Childhood obesity and insulin resistance in a Yucatan mini-piglet model : putative roles of IGF-1 and muscle PPARs in adipose tissue activity and development
184. Bioavailability of starch, rate of glucose absorption and intestinal metabolism in pigs
185. Measurement of exogenous acetate production during colonic fermentation of lactulose using (1-13C) acetate in humans
186. Thiazolidinedione use is not associated with worse cardiovascular outcomes: A study in 28,332 high risk patients with diabetes in routine clinical practice
187. Diagnostic et traitement des hypercholestérolémies familiales (HF) chez l’adulte : recommandations de la Nouvelle société française d’athérosclérose (NSFA)
188. Acebutolol and alprenolol metabolism predictions: comparative study of electrochemical and cytochrome P450-catalyzed reactions using liquid chromatography coupled to high-resolution mass spectrometry
189. In situ NMR spectroelectrochemistry for the structure elucidation of unstable intermediate metabolites
190. Omega 3 Fatty Acids Promote Macrophage Reverse Cholesterol Transport in Hamster Fed High Fat Diet
191. Voltammetry coupled to mass spectrometry in the presence of isotope 18O labeled water for the prediction of oxidative transformation pathways of activated aromatic ethers: Acebutolol
192. Integration of microbiology and infectious disease teaching courses in an interdisciplinary training programme (Master level) centred on the 'One world, one health' WHO concept.
193. Direct and maternal n-3 long-chain polyunsaturated fatty acid supplementation improved triglyceridemia and glycemia through the regulation of hepatic and muscle sphingolipid synthesis in offspring hamsters fed a high-fat diet.
194. Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes
195. Aliment et santé. Quels glucoses dans les aliments pour garantir notre santé ?
196. Kinetic aspects of acetate metabolism in healthy humans using (1 -13 C) acetate
197. Exploration du métabolisme par les isotopes stables in vivo chez l'homme
198. Low Rate of Production of Apolipoproteins B100 and AI in 2 Patients With Anderson Disease (Chylomicron Retention Disease)
199. Electrochemical oxidation behavior of Acebutolol and identification of intermediate species by liquid chromatography and mass spectrometry
200. Abstract 131: PCSK9: A Biomarker Associated with the Metabolic Complications of Morbid Obesity
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.